Sugi Predict

Sugi Predict / Targets / PDE6C

PDE6C

Cone cGMP-specific 3',5'-cyclic phosphodiesterase subunit alpha' · P51160 · PDE6C on Sugi Atlas →

15,846 patent compounds predicted against PDE6C, 13,149 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL1891582 SCHEMBL1891582 0.59 8/20
SCHEMBL1887267 SCHEMBL1887267 0.45 8/20
SCHEMBL1327741 SCHEMBL1327741 0.79 6/20
SCHEMBL1327318 SCHEMBL1327318 0.81 5/20
SCHEMBL1327321 SCHEMBL1327321 0.81 5/20
SCHEMBL1327324 SCHEMBL1327324 0.81 5/20
SCHEMBL972494 SCHEMBL972494 0.72 5/20
SCHEMBL972096 SCHEMBL972096 0.60 5/20
SCHEMBL969605 SCHEMBL969605 0.77 4/20
SCHEMBL969760 SCHEMBL969760 0.51 4/20
SCHEMBL1696249 SCHEMBL1696249 0.51 4/20
SCHEMBL147337 SCHEMBL147337 1.00 3/20
SCHEMBL145682 SCHEMBL145682 0.77 3/20
SCHEMBL1071 SCHEMBL1071 0.76 3/20
SCHEMBL2031422 SCHEMBL2031422 0.73 3/20
SCHEMBL968670 SCHEMBL968670 0.73 3/20
SCHEMBL972290 SCHEMBL972290 0.73 3/20
SCHEMBL971800 SCHEMBL971800 0.72 3/20
SCHEMBL867299 SCHEMBL867299 0.72 3/20
SCHEMBL1326458 SCHEMBL1326458 0.72 3/20

Clinical trials — most relevant to PDE6C by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Management of Retinitis Pigmentosa Via Combination of Wharton's Jelly-derived Mesenchymal Stem Cells and Magnovision PHASE3COMPLETED
Oral N-acetylcysteine for Retinitis Pigmentosa PHASE3ACTIVE_NOT_RECRUITING
Randomized Trial of Vitamin A and Vitamin E Supplementation for Retinitis Pigmentosa PHASE3COMPLETED
PDE6A Gene Therapy for Retinitis Pigmentosa PHASE1/PHASE2ACTIVE_NOT_RECRUITING
The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients PHASE1/PHASE2WITHDRAWN
Promising ROd-cone DYstrophy Gene therapY PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Subtenon Autologous Platelet-Rich Plasma in Inherited and Degenerative Retinal Diseases PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Intravitreal Adalimumab in Inherited and Degenerative Retinal Diseases PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Intravitreal Dexamethasone Implant in Retinitis Pigmentosa-related Macular Edema- a Retrospective Study PHASE2UNKNOWN
Study of Oral Minocycline in Treating Bilateral Cystoid Macular Edema Associated With Retinitis Pigmentosa PHASE1/PHASE2COMPLETED
Pentoxifylline as an Adjunctive in Treatment of Negative Symptoms in Chronic Schizophrenia PHASE1/PHASE2COMPLETED
Multi-Center Study to Evaluate the Efficacy and Safety of Sildenafil Cream (3.6%) in Premenopausal Patients With Female Sexual Arousal Disorder PHASE2UNKNOWN
A Phase 1/2, First-in-Human Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of a Subretinal Injection of SB-007 in Subjects With Stargardt Disease (STGD1) PHASE1/PHASE2RECRUITING
Safety Study of Sildenafil in Treatment of Cerebral Aneurysm Vasospasm PHASE2WITHDRAWN
Title: Evaluation of a Novel PET Radioligand for Phosphodiesterase-4D (PDE4D) PHASE1/PHASE2COMPLETED
Evaluation of Safety of Ciliary Neurotrophic Factor Implants in the Eye PHASE1COMPLETED
Investigating the Effect of Vitamin A Supplementation on Retinitis Pigmentosa PHASE1COMPLETED
Single-Dose Relative Bioavailability Study of SST-6006, a Topical Sildenafil Cream Versus Oral Sildenafil in Healthy Male Adults PHASE1COMPLETED
A Open-Label, Within-Subject Dose-Escalation Study to Evaluate the Clinical Safety and Pharmacokinetic Profile of a Topical Sildenafil Cream (5% w/w), in Healthy Postmenopausal Women PHASE1COMPLETED
Clinical Characterization on PDE6A-related Retinitis Pigmentosa in Preparation to a Gene Therapy Trial nanCOMPLETED
Natural History Study in Patients With PDE6A-, PDE6B- and RHO-linked Retinitis Pigmentosa nanACTIVE_NOT_RECRUITING
Prospective Natural History Study of Retinitis Pigmentosa nanACTIVE_NOT_RECRUITING
Retrospective Natural History Study of Retinitis Pigmentosa nanUNKNOWN
Rod Sensitivity in Age-related Macular Degeneration (AMD) and Retinitis Pigmentosa (RP) nanCOMPLETED
Is Pentoxifylline Able to Improve Olfactory Sensitivity? nanCOMPLETED
Management of Cystoid Macular Edema Secondary to Retinitis Pigmentosa Via Subliminal Micropulse Yellow Laser nanCOMPLETED
Identifying Genes and Mutations Underlying Retinitis Pigmentosa and Allied Diseases nanUNKNOWN
The Natural History of the Progression of Atrophy Secondary to Stargardt Disease Type 4: PROM1-Related Macular Dystrophy nanCOMPLETED
Sildenafil Citrate Added to Low Molecular Weight Heparin and Low Dose Aspirin in High-risk Pregnancy nanWITHDRAWN
CNGB1 and Allied Disorders nanSUSPENDED

Related proteins — ESM-2 sequence neighbours (a PDE6C binder may also engage these)

ProteinNameSimilarity
P16586 — 1.000 P16586 →
P52731 — 1.000 P52731 →
PDE6A Rod cGMP-specific 3',5'-cyclic phosphodiesterase subunit alpha 1.000 landscape →
Q28263 — 1.000 Q28263 →
P11541 — 1.000 P11541 →
Q91ZQ1 — 1.000 Q91ZQ1 →
P27664 — 1.000 P27664 →
P23439 — 0.999 P23439 →
P33726 — 0.999 P33726 →
P23440 — 0.999 P23440 →
PDE6B Rod cGMP-specific 3',5'-cyclic phosphodiester 0.998 landscape →
B4LVU6 — 0.994 B4LVU6 →
PDE5A cGMP-specific 3',5'-cyclic phosphodiesterase 0.992 landscape →
Q1KKS3 — 0.991 Q1KKS3 →
P91119 — 0.990 P91119 →
PDE11A Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A 0.990 landscape →
B3LVW5 — 0.990 B3LVW5 →
O77746 — 0.989 O77746 →
O54735 — 0.989 O54735 →
Q8CG03 — 0.989 Q8CG03 →
Q298P4 — 0.988 Q298P4 →
Q8VID6 — 0.988 Q8VID6 →
P0C1Q2 — 0.987 P0C1Q2 →
B4K9L4 — 0.987 B4K9L4 →
Q9VFI9 — 0.987 Q9VFI9 →
B3P3K2 — 0.986 B3P3K2 →
Q28156 — 0.986 Q28156 →
B4PSS5 — 0.986 B4PSS5 →
B4NAL6 — 0.986 B4NAL6 →
Q6NNF2 — 0.986 Q6NNF2 →